echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Express reduces opioid consumption by nearly 80%, and the clinical results of long-acting local analgesics phase 3 are positive

    Express reduces opioid consumption by nearly 80%, and the clinical results of long-acting local analgesics phase 3 are positive

    • Last Update: 2022-10-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ▎Editor of WuXi AppTec content team

    Recently, Pacira BioSciences published positive data
    from a Phase 3 clinical trial of its drug EXPAREL as a single-dose popliteal sciatic blocker for postoperative local analgesia in patients undergoing bunion resection.



    Image source: 123RF


    Papira plans to file a Supplement New Drug Application (sNDA) with the FDA early next year to expand the scope of the EXPAREL label to include sciatic block in the popliteal fossa and femoral nerve block in the adductor tube
    .


    WuXi AppTec provides integrated, end-to-end new drug development and manufacturing services to the global biopharmaceutical industry, covering the fields
    of chemical drug development and production, biological research, preclinical testing and clinical trial development, cell and gene therapy development, testing and production.

    If you have relevant business needs, please click on the picture below to fill in the specific information
    .


    ▲If you have any business needs, please long press to scan the QR code above, or

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.